The emergence of blood-based biomarkers is transforming the diagnostic landscape for Alzheimer’s disease, offering the potential to make the identification of disease-related pathology more accessible, scalable and less invasive. Among these biomarkers, phosphorylated tau 217 (p-tau217) has gained significant attention for its ability to detect Alzheimer’s-related pathology and complement established diagnostic approaches such as amyloid PET imaging and cerebrospinal fluid (CSF) analysis.
ALZpath’s proprietary p-tau217 antibody has been extensively studied in peer-reviewed research and is being integrated into automated in vitro diagnostic platforms to support broader clinical adoption. The development of assays such as Beckman Coulter’s Access p-Tau217 assay could help bring blood-based biomarker testing into routine laboratory workflows, potentially supporting earlier and more efficient assessment of patients presenting with cognitive impairment.
In this written Q&A with MedTech Spectrum, Mike Banville, CEO & President, ALZpath, discusses the clinical and operational potential of blood-based p-tau217 testing, the scientific validation underpinning ALZpath’s antibody, and the importance of analytical consistency and regulatory evaluation. He also shares insights into how automated testing platforms could support scalable Alzheimer’s diagnostics and contribute to more objective clinical decision-making.
Blood-based biomarkers are increasingly being viewed as a complementary approach to PET imaging and cerebrospinal fluid (CSF) testing. What advantages does the Access p-Tau217 assay offer in terms of accessibility, scalability, workflow efficiency, and cost-effectiveness for healthcare providers?
Blood-based pTau217 biomarker testing represents an important advance in identifying Alzheimer’s disease-related pathology, offering a complementary tool alongside established traditional gold standards like amyloid PET imaging and cerebrospinal fluid (CSF) analysis. When integrated thoughtfully into clinical care pathways, the Access p-Tau217 assay can support earlier, more objective identification of Alzheimer’s-related pathology in patients presenting with mild cognitive impairment (MCI) or cognitive decline, while keeping clinical judgment central to patient care.
In terms of accessibility, a simple blood draw can offer a significantly less invasive option to lumbar punctures while alleviating patient reliance on specialized imaging facilities that often face capacity constraints and long waiting times.
By leveraging automated, high-throughput diagnostic analyzer infrastructure, the Access pTau217 assay could offer scalability by enabling healthcare systems to integrate testing within existing clinical laboratory workflows and expand access across broad healthcare networks without requiring specialized, resource-intensive infrastructure.
Integrating pTau217 biomarker testing early in the diagnostic pathway can serve as a triage tool to identify patients with suspected cognitive impairment who are most likely to have underlying amyloid pathology. This can help prioritize appropriate patients for further diagnostic evaluation and specialist referral while informing treatment-readiness discussions earlier in the care pathway.
Blood-based biomarker testing can support economic sustainability by offering healthcare systems a cost-effective diagnostic approach compared to costly PET scans, while helping to manage growing diagnostic demand across aging populations.
The assay was developed using ALZpath's antibody, which has been widely validated in scientific literature. Could you elaborate on the scientific and clinical validation process behind the assay, and how this translates into confidence for clinicians and laboratories?
ALZpath's proprietary p-tau217 antibody is the most extensively tested and validated biomarker for detecting Alzheimer’s disease pathology.
Validated in over 200 peer-reviewed publications, the antibody has consistently demonstrated strong sensitivity and accuracy in blood-based detection, in concordance with traditional “gold standards” like amyloid PET scans and CSF testing.
This extensive scientific foundation transitions into clinical utility through integration into automated diagnostic platforms by industry leaders like Beckman Coulter and Roche. Most recently, Beckman Coulter's Access p-Tau217 assay received the CE mark under IVDR, reflecting formal regulatory review of its analytical performance. This milestone indicates that Beckman Coulter has demonstrated a highly consistent ability to measure pTau217 on their DxI fully automated clinical diagnostic instrument. Moving the antibody into regulated, high-throughput in vitro diagnostic assays subjects it to strict analytical testing for lot-to-lot consistency, precision, and broad population reliability.
For clinicians, extensive validation inspires confidence by offering an evidence-backed, non-invasive method to evaluate Alzheimer's pathology in patients evaluated for cognitive impairment. This supports clear clinical decision-making, treatment-readiness evaluations, and objective discussion regarding patient management.
For laboratories, standardizing the pTau217 antibody on automated laboratory platforms ensures reproducible, high-quality results across routine laboratory operations, helping close evidence gaps and advancing consistent standards of care.
